ABI-6250 not checked

Assembly Biosciences

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Once daily tablet dosing for 48 weeks, starting at Week 16 visit”In the company’s words, NCT07762027 on ClinicalTrials.gov
Tested for
Chronic Hepatitis D Infection, Mild Hepatic Imparement
Main trialPhase 2
“This study is designed to assess safety, pharmacokinetics, and efficacy ABI-6250 in participants with Chronic Hepatitis D Virus Infection.”In the company’s words, NCT07762027 on ClinicalTrials.gov

Other drugs for Chronic Hepatitis D Infection

All 7 drugs for Chronic Hepatitis D Infection

Coming up2

Changes1

Last 90 days

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Jun 2027 A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection
Phase 1Recruiting Apr 2027 A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function
Phase 1Completed 8 Jul 2025 A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ABI-6250

Following is part of Solo: you see every change to ABI-6250 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in